Global Synovial Sarcoma Treatment Market – Industry Trends and Forecast to 2030

 Análise e dimensão do mercado de tratamento do sarcoma sinovial

O sarcoma sinovial é um cancro relativamente incomum, classificado como sarcoma de tecidos moles (STS) com diferenciação incerta. É responsável por 5-10% de todos os STS. A incidência ajustada por idade em crianças é de 0,81/1.000.000 e 1,42/1.000.000 em adultos, sendo que aproximadamente 1.000 doentes são diagnosticados com sarcoma sinovial a cada ano nos Estados Unidos. O sarcoma sinovial difere das outras STS porque surge numa idade média de início mais jovem, é mais comum em adolescentes e jovens adultos (idade média de diagnóstico de 39 anos) e afeta igualmente ambos os sexos. O sarcoma sinovial é o STS não rabdomiossarcoma mais comum em crianças, sendo responsável por 30% de todos os diagnósticos de STS.

A Data Bridge Market Research analisa que o mercado de tratamento do sarcoma sinovial, que foi de 38,5 mil milhões de dólares em 2022, deverá atingir os 56,88 mil milhões de dólares até 2030, com um CAGR de 5% durante o período de previsão de 2023 a 2030. Além dos insights sobre o mercado cenários como o valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análise especializada aprofundada, epidemiologia de pacientes, análise pipeline, análise de preços e estrutura regulatória.

Âmbito e segmentação do mercado de tratamento do sarcoma sinovial  

Definição de mercado

O sarcoma sinovial é um tipo raro de cancro que se desenvolve junto a grandes articulações, principalmente no joelho. É mais provável que esta doença afete pessoas entre os 15 e os 40 anos. Também é conhecido como mieloma maligno. Os sintomas mais comuns do sarcoma sinovial são o inchaço junto às zonas afetadas, que é geralmente indolor, e problemas no uso das pernas e das mãos. O sarcoma sinovial é caracterizado pelo crescimento anormal dos tecidos moles. O sarcoma sinovial é altamente metastático e dissemina-se para outros locais em quase 50% dos casos, sendo os pulmões o local mais comum de metástase. A causa do sarcoma sinovial ainda não foi determinada, no entanto, tem sido associada a anomalias do cromossoma X e do cromossoma 18 nas células tumorais.

Dinâmica global do mercado de tratamento do sarcoma sinovial

Motoristas

• Aumento da incidência de sarcoma sinovial

De acordo com a American Cancer Society, a incidência de sarcoma sinovial nos Estados Unidos em 2018 deverá ser de 13.040 doentes, sendo 7.370 homens e 5.670 mulheres. Espera-se que uma extensa investigação e desenvolvimento neste campo para o desenvolvimento de novas terapias para o tratamento do sarcoma sinovial impulsionem o crescimento do mercado global de tratamento do sarcoma sinovial durante o período de previsão. Por exemplo, a Accuronix Therapeutics, a Advenchen Laboratories, LLC, a Immune Design, a Cue Biopharma e outras, estão a realizar investigação e desenvolvimento de novos candidatos à imunoterapia para o tratamento do sarcoma sinovial.

• Avanços tecnológicos

A Food and Drug Administration (FDA) dos EUA designou a terapia com células T NY-ESO-1 da Adaptimmune Therapeutics como um avanço na terapia com células T. A Immunocore, uma empresa de biotecnologia sediada no Reino Unido, está a desenvolver o ImmTAC (TCRs monoclonais de mobilização imunitária), que tem potenciais aplicações numa variedade de cancros, incluindo o sarcoma sinovial. Além disso, estão em curso pesquisas sobre novas vacinas para o tratamento do sarcoma sinovial, que poderão alargar as opções de tratamento para a doença. Durante o período de previsão, estes fatores impulsionam o crescimento do mercado de tratamento do sarcoma sinovial.

Oportunidades

• Aumento dos ensaios clínicos

A robust and promising clinical pipeline is expected to fuel the synovial sarcoma treatment market in the near future. There are 83 pipeline therapeutics for synovial sarcoma treatment, with 8 drugs in clinical phase III. In addition, novel technologies such as ZVex and GLAAS technology, RESOLYSIN technology, and tumor-specific cytotoxic T-cell treatment are yielding promising results. Thus, a significant pipeline of drugs, growing public awareness, and increased funding for research are major factors driving market growth.

Restraints/Challenges

• High costs

The side effects associated with cancer treatment, high costs and uncertainty of the results of clinical trials are expected to affect the market's growth during the forecast period.

This synovial sarcoma treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the synovial sarcoma treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In Dec 2019, Adaptimmune Therapeutics plc announced that it has received the FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ADP-A2M4 to treat synovial sarcoma.

Global Synovial Sarcoma Treatment Market Scope

The synovial sarcoma treatment market is segmented on the basis of diagnosis, type, treatment, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Imaging
• Biopsy
• Others

Type

• ACXT-3102
• AL-3818
• Axitinib
• CMB-305
• CUE-102
• Others

 Treatment

• Surgery
• Anti-Angiogenesis
• Drugs Radiation Therapy
• Chemotherapy

 End-Users

• Hospitals
• Specialty Clinics
• Oncology Centers
• Others

 Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Synovial Sarcoma Treatment Market Regional Analysis/Insights

The synovial sarcoma treatment market is analyzed and market size insights and trends are provided by country, diagnosis, type, treatment, end-users and distribution channel as referenced above.

The countries covered in the synovial sarcoma treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the synovial sarcoma treatment market due to the presence of key manufacturers of the product is high and growing healthcare expenditure, research and development activities which contributes to raising the significant market growth.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to improve the new research and developments on synovial sarcoma treatment market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The synovial sarcoma treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for synovial sarcoma treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the synovial sarcoma treatment market. The data is available for historic period 2011-2021.

Competitive Landscape and Synovial Sarcoma Treatment Market Share Analysis

The synovial sarcoma treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to synovial sarcoma treatment market.

Some of the major players operating in the synovial sarcoma treatment market are:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Bayer AG (Germany)
• Epizyme (U.S.)
• Cue Biopharma (U.S.)
• Eli Lilly and Company (U.S.)
• Adaptimmune Therapeutics Plc (U.K.)
• Advenchen Laboratories LLC (U.S.)
• EpiZyme Inc (U.S.)
• Merck & Co., Inc (U.S.)
• Immunocore Ltd (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Karyopharm Therapeutics Inc (U.S.)
• Novartis AG (Switzerland)
• Pfizer Inc. (U.S.)
• Takara Bio Inc (Japan) 

SKU-56902